Published in Semin Radiat Oncol on October 01, 2010
The role of PARP in DNA repair and its therapeutic exploitation. Br J Cancer (2011) 1.71
PTEN deletion in prostate cancer cells does not associate with loss of RAD51 function: implications for radiotherapy and chemotherapy. Clin Cancer Res (2011) 1.46
New paradigms and future challenges in radiation oncology: an update of biological targets and technology. Sci Transl Med (2013) 1.35
Autophagy-dependent senescence in response to DNA damage and chronic apoptotic stress. Autophagy (2012) 1.17
PET-CT for radiotherapy treatment planning and response monitoring in solid tumors. Nat Rev Clin Oncol (2011) 1.11
Response of human prostate cancer cells and tumors to combining PARP inhibition with ionizing radiation. Mol Cancer Ther (2011) 1.08
Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1. Cell Cycle (2011) 1.05
Topoisomerase I inhibition in colorectal cancer: biomarkers and therapeutic targets. Br J Cancer (2011) 1.05
An arranged marriage for precision medicine: hypoxia and genomic assays in localized prostate cancer radiotherapy. Br J Radiol (2014) 1.04
A Phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy in patients with advanced solid malignancies and peritoneal carcinomatosis. Clin Cancer Res (2014) 0.98
Improving the efficacy of chemoradiation with targeted agents. Cancer Discov (2014) 0.97
The ups and downs of DNA repair biomarkers for PARP inhibitor therapies. Am J Cancer Res (2010) 0.95
Tumor hypoxia as a driving force in genetic instability. Genome Integr (2013) 0.92
Preventive evolutionary medicine of cancers. Evol Appl (2012) 0.91
Molecular Pathways: Overcoming Radiation Resistance by Targeting DNA Damage Response Pathways. Clin Cancer Res (2015) 0.90
DNA damage response and repair: insights into strategies for radiation sensitization of gliomas. Future Oncol (2011) 0.89
A preclinical study combining the DNA repair inhibitor Dbait with radiotherapy for the treatment of melanoma. Neoplasia (2014) 0.85
Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer. BMC Cancer (2015) 0.83
Evaluation of the efficacy of radiation-modifying compounds using γH2AX as a molecular marker of DNA double-strand breaks. Genome Integr (2011) 0.82
Altering the response to radiation: sensitizers and protectors. Semin Oncol (2014) 0.81
HPV Positive Head and Neck Cancers: Molecular Pathogenesis and Evolving Treatment Strategies. Cancers (Basel) (2016) 0.80
Radiation-induced alterations in histone modification patterns and their potential impact on short-term radiation effects. Front Oncol (2012) 0.79
Personalized radiotherapy: concepts, biomarkers and trial design. Br J Radiol (2015) 0.77
Defining genome maintenance pathways using functional genomic approaches. Crit Rev Biochem Mol Biol (2011) 0.77
Linking the history of radiation biology to the hallmarks of cancer. Radiat Res (2014) 0.76
BRCA1 Mutation: A Predictive Marker for Radiation Therapy? Int J Radiat Oncol Biol Phys (2015) 0.76
Radiation oncology in vitro: trends to improve radiotherapy through molecular targets. Biomed Res Int (2014) 0.76
PARP1 inhibition radiosensitizes HNSCC cells deficient in homologous recombination by disabling the DNA replication fork elongation response. Oncotarget (2016) 0.76
Synthetic lethal targeting of PTEN-deficient cancer cells using selective disruption of polynucleotide kinase/phosphatase. Mol Cancer Ther (2013) 0.75
The Chk1 inhibitor MK-8776 increases the radiosensitivity of human triple-negative breast cancer by inhibiting autophagy. Acta Pharmacol Sin (2017) 0.75
Carbogen gas and radiotherapy outcomes in prostate cancer. Ther Adv Urol (2013) 0.75
Chk2 is a tumor suppressor that regulates apoptosis in both an ataxia telangiectasia mutated (ATM)-dependent and an ATM-independent manner. Mol Cell Biol (2002) 3.08
Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment. Cancer Res (2010) 2.68
Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells. Mol Cell Biol (2004) 2.09
Hypoxia-induced down-regulation of BRCA1 expression by E2Fs. Cancer Res (2005) 2.02
Inverse relationship between biochemical outcome and acute toxicity after image-guided radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys (2011) 2.00
Gold nanoparticles as radiation sensitizers in cancer therapy. Radiat Res (2010) 1.97
MRE11 promotes AKT phosphorylation in direct response to DNA double-strand breaks. Cell Cycle (2011) 1.97
Ionizing radiation activates AMP-activated kinase (AMPK): a target for radiosensitization of human cancer cells. Int J Radiat Oncol Biol Phys (2010) 1.89
Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance. Cancer Res (2008) 1.70
Protease nexin 1 inhibits hedgehog signaling in prostate adenocarcinoma. J Clin Invest (2012) 1.57
PTEN deletion in prostate cancer cells does not associate with loss of RAD51 function: implications for radiotherapy and chemotherapy. Clin Cancer Res (2011) 1.46
TMPRSS2-ERG status is not prognostic following prostate cancer radiotherapy: implications for fusion status and DSB repair. Clin Cancer Res (2013) 1.45
MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer. Cancer Res (2010) 1.44
Promyelocytic leukemia nuclear bodies behave as DNA damage sensors whose response to DNA double-strand breaks is regulated by NBS1 and the kinases ATM, Chk2, and ATR. J Cell Biol (2006) 1.43
From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. J Pathol (2012) 1.42
Drug-induced endocrine and metabolic disorders. Drug Saf (2007) 1.42
Rnf8 deficiency impairs class switch recombination, spermatogenesis, and genomic integrity and predisposes for cancer. J Exp Med (2010) 1.40
A novel poly(ADP-ribose) polymerase inhibitor, ABT-888, radiosensitizes malignant human cell lines under hypoxia. Radiother Oncol (2008) 1.39
The MMS22L-TONSL complex mediates recovery from replication stress and homologous recombination. Mol Cell (2010) 1.32
Novel chemical enhancers of heat shock increase thermal radiosensitization through a mitotic catastrophe pathway. Cancer Res (2007) 1.32
The p53 protein family and radiation sensitivity: Yes or no? Cancer Metastasis Rev (2004) 1.24
Reprogramming metabolism with metformin improves tumor oxygenation and radiotherapy response. Clin Cancer Res (2013) 1.24
Copy number alterations of c-MYC and PTEN are prognostic factors for relapse after prostate cancer radiotherapy. Cancer (2012) 1.23
Hypoxia down-regulates DNA double strand break repair gene expression in prostate cancer cells. Radiother Oncol (2005) 1.22
Treatment of radiation proctitis with hyperbaric oxygen. Radiother Oncol (2005) 1.18
Late residual gamma-H2AX foci in murine skin are dose responsive and predict radiosensitivity in vivo. Radiat Res (2010) 1.17
Evidence for the direct binding of phosphorylated p53 to sites of DNA breaks in vivo. Cancer Res (2005) 1.16
Tumor hypoxia, DNA repair and prostate cancer progression: new targets and new therapies. Future Oncol (2007) 1.15
Defective DNA strand break repair after DNA damage in prostate cancer cells: implications for genetic instability and prostate cancer progression. Cancer Res (2004) 1.13
Comparing oxygen-sensitive MRI (BOLD R2*) with oxygen electrode measurements: a pilot study in men with prostate cancer. Int J Radiat Biol (2009) 1.13
Combined-modality treatment of solid tumors using radiotherapy and molecular targeted agents. J Clin Oncol (2003) 1.11
Targeting homologous recombination using imatinib results in enhanced tumor cell chemosensitivity and radiosensitivity. Mol Cancer Ther (2009) 1.11
"Contextual" synthetic lethality and/or loss of heterozygosity: tumor hypoxia and modification of DNA repair. Clin Cancer Res (2010) 1.11
High-resolution array CGH identifies novel regions of genomic alteration in intermediate-risk prostate cancer. Prostate (2009) 1.08
Radiation and new molecular agents part I: targeting ATM-ATR checkpoints, DNA repair, and the proteasome. Semin Radiat Oncol (2006) 1.08
Microscopic imaging of DNA repair foci in irradiated normal tissues. Int J Radiat Biol (2009) 1.08
Integrated genome and transcriptome sequencing identifies a novel form of hybrid and aggressive prostate cancer. J Pathol (2012) 1.07
Nutlin-3 radiosensitizes hypoxic prostate cancer cells independent of p53. Mol Cancer Ther (2008) 1.03
Tumor cell kill by c-MYC depletion: role of MYC-regulated genes that control DNA double-strand break repair. Cancer Res (2010) 1.02
miRNA-95 mediates radioresistance in tumors by targeting the sphingolipid phosphatase SGPP1. Cancer Res (2013) 1.02
Analysis of variants in DNA damage signalling genes in bladder cancer. BMC Med Genet (2008) 0.99
Inhibition of breast cancer local relapse by targeting p70S6 kinase activity. J Mol Cell Biol (2013) 0.99
Discordance between phosphorylation and recruitment of 53BP1 in response to DNA double-strand breaks. Cell Cycle (2012) 0.98
NKX3.1 haploinsufficiency is prognostic for prostate cancer relapse following surgery or image-guided radiotherapy. Clin Cancer Res (2011) 0.96
Alterations in DNA repair gene expression under hypoxia: elucidating the mechanisms of hypoxia-induced genetic instability. Ann N Y Acad Sci (2005) 0.96
Ionizing radiation regulates the expression of AMP-activated protein kinase (AMPK) in epithelial cancer cells: modulation of cellular signals regulating cell cycle and survival. Radiother Oncol (2012) 0.95
Optimal treatment of intermediate-risk prostate carcinoma with radiotherapy: clinical and translational issues. Cancer (2005) 0.94
PRIMA-1(met) radiosensitizes prostate cancer cells independent of their MTp53-status. Radiother Oncol (2008) 0.94
DNA repair targeting and radiotherapy: a focus on the therapeutic ratio. Semin Radiat Oncol (2010) 0.93
Longitudinal cytokine expression during IMRT for prostate cancer and acute treatment toxicity. Clin Cancer Res (2009) 0.92
Resveratrol enhances prostate cancer cell response to ionizing radiation. Modulation of the AMPK, Akt and mTOR pathways. Radiat Oncol (2011) 0.92
Chronic hypoxia compromises repair of DNA double-strand breaks to drive genetic instability. J Cell Sci (2012) 0.92
Direct observation of ultrafast-electron-transfer reactions unravels high effectiveness of reductive DNA damage. Proc Natl Acad Sci U S A (2011) 0.92
ShatterProof: operational detection and quantification of chromothripsis. BMC Bioinformatics (2014) 0.91
Inherently multimodal nanoparticle-driven tracking and real-time delineation of orthotopic prostate tumors and micrometastases. ACS Nano (2013) 0.88
Neoadjuvant radiotherapy for locally advanced and high-risk prostate cancer. Nat Rev Clin Oncol (2010) 0.88
Intratumoral hypoxia as the genesis of genetic instability and clinical prognosis in prostate cancer. Adv Exp Med Biol (2014) 0.87
Radiation effects and radioprotection in MC3T3-E1 mouse calvarial osteoblastic cells. Plast Reconstr Surg (2008) 0.87
Hypoxia disrupts the Fanconi anemia pathway and sensitizes cells to chemotherapy through regulation of UBE2T. Radiother Oncol (2011) 0.86
Education and training for radiation scientists: radiation research program and American Society of Therapeutic Radiology and Oncology Workshop, Bethesda, Maryland, May 12-14, 2003. Radiat Res (2003) 0.86
Molecular markers predicting radiotherapy response: report and recommendations from an International Atomic Energy Agency technical meeting. Int J Radiat Oncol Biol Phys (2005) 0.86
Long-term outcome of radiation-based conservation therapy for invasive bladder cancer. Urol Oncol (2007) 0.86
Imatinib radiosensitizes bladder cancer by targeting homologous recombination. Cancer Res (2013) 0.86
Biomarkers for DNA DSB inhibitors and radiotherapy clinical trials. Cancer Metastasis Rev (2008) 0.86
High tumor interstitial fluid pressure identifies cervical cancer patients with improved survival from radiotherapy plus cisplatin versus radiotherapy alone. Int J Cancer (2014) 0.85
Primary esophageal and gastro-esophageal junction cancer xenograft models: clinicopathological features and engraftment. Lab Invest (2013) 0.85
Homologous recombination and prostate cancer: a model for novel DNA repair targets and therapies. Radiother Oncol (2007) 0.84
Current treatment strategies for epistaxis: a multidisciplinary approach. J Neurointerv Surg (2012) 0.84
The receptor tyrosine kinase inhibitor amuvatinib (MP470) sensitizes tumor cells to radio- and chemo-therapies in part by inhibiting homologous recombination. Radiother Oncol (2011) 0.84
WTp53 induction does not override MTp53 chemoresistance and radioresistance due to gain-of-function in lung cancer cells. Mol Cancer Ther (2008) 0.84
Protein-protein interactions occur between p53 phosphoforms and ATM and 53BP1 at sites of exogenous DNA damage. Radiat Res (2011) 0.84
Practical approaches to proteomic biomarkers within prostate cancer radiotherapy trials. Cancer Metastasis Rev (2008) 0.84
AZD5438, an inhibitor of Cdk1, 2, and 9, enhances the radiosensitivity of non-small cell lung carcinoma cells. Int J Radiat Oncol Biol Phys (2012) 0.83
Array CGH as a potential predictor of radiocurability in intermediate risk prostate cancer. Acta Oncol (2010) 0.83
Radiation Therapy Oncology Group translational research program stem cell symposium: incorporating stem cell hypotheses into clinical trials. Int J Radiat Oncol Biol Phys (2009) 0.83
Analysis of the expression and function of the small heat shock protein gene, hsp27, in Xenopus laevis embryos. Comp Biochem Physiol A Mol Integr Physiol (2006) 0.83
Pathological predictors for site of local recurrence after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys (2012) 0.82
Detection of genetic instability at HER-2/neu and p53 loci in breast cancer cells sing Comet-FISH. Breast Cancer Res Treat (2005) 0.82
Efficacy of combining GMX1777 with radiation therapy for human head and neck carcinoma. Clin Cancer Res (2010) 0.82
Electron transfer-based combination therapy of cisplatin with tetramethyl-p-phenylenediamine for ovarian, cervical, and lung cancers. Proc Natl Acad Sci U S A (2012) 0.81
Hypoxia and cellular localization influence the radiosensitizing effect of gold nanoparticles (AuNPs) in breast cancer cells. Radiat Res (2014) 0.81
Investigations of antioxidant-mediated protection and mitigation of radiation-induced DNA damage and lipid peroxidation in murine skin. Int J Radiat Biol (2013) 0.80
A phase I trial of pre-operative radiotherapy for prostate cancer: clinical and translational studies. Radiother Oncol (2008) 0.80
4FISH-IF, a four-color dual-gene FISH combined with p63 immunofluorescence to evaluate NKX3.1 and MYC status in prostate cancer. J Histochem Cytochem (2013) 0.80
Allelic loss of the loci containing the androgen synthesis gene, StAR, is prognostic for relapse in intermediate-risk prostate cancer. Prostate (2011) 0.80
Overview of cancer molecular radiobiology. Cancer Treat Res (2008) 0.79
Corrigendum: analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. Nat Genet (2015) 0.79
Tumor hypoxia as a modifier of DNA strand break and cross-link repair. Curr Mol Med (2009) 0.79
In situ DNA repair assays as guides to personalized breast cancer chemotherapeutics: ready for prime time? J Clin Oncol (2011) 0.79
WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma. Acta Neuropathol Commun (2014) 0.79
The therapeutic ratio is preserved for radiotherapy or cisplatin treatment in BRCA2-mutated prostate cancers. Can Urol Assoc J (2011) 0.78
A role for p53 in the response of bystander cells to receipt of medium borne signals from irradiated cells. Int J Radiat Biol (2011) 0.78
Tumor senescence and radioresistant tumor-initiating cells (TICs): let sleeping dogs lie! Breast Cancer Res (2010) 0.78
Biodosimetry using radiation-induced micronuclei in skin fibroblasts. Int J Radiat Biol (2011) 0.77
Clonality of localized and metastatic prostate cancer. Curr Opin Urol (2016) 0.77
Synergistic nanoparticulate drug combination overcomes multidrug resistance, increases efficacy, and reduces cardiotoxicity in a nonimmunocompromised breast tumor model. Mol Pharm (2014) 0.76